Applied Therapeutics, Inc. (APLT) | Investment Case

1. Company Snapshot

1.a. Company Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.

Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.Applied Therapeutics, Inc.was incorporated in 2016 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on APLT

Negative drivers behind Applied Therapeutics, Inc.'s recent stock performance include a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for govorestat, a novel CNS-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia. This setback has led to multiple securities lawsuits filed against the company and its senior executives for potential violations of federal securities laws. Investors are advised to contact various law firms for more information regarding possible lead plaintiff appointment, adding to the overall uncertainty and negativity surrounding the stock.

1.c. Company Highlights

Last Price	0.22
Change Percentage	-5.79%
Open	0.23
Previous Close	0.23
Market Cap ( Millions)	31
Volume	5773476
Year High	1.5
Year Low	0.2
M A 50	0.82
M A 200	0.53

FCF Yield	-278.60%
Dividend Yield	0.00%
ROE	-65.63%
Debt / Equity	-445.63%
Net Debt / EBIDTA	9.41%
Price To Book	-56.2
Price Earnings Ratio	-1.74
Price To FCF	-0.36
Price To sales	31.17
EV / EBITDA	-0.22

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Applied Therapeutics (APLT) Upgraded to Buy: Here's Why

Nov -27

Source: zacks.com

Applied Therapeutics Announces Corporate Updates

Nov -20

Source: globenewswire.com

Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain

Nov -13

Source: benzinga.com

Applied Therapeutics Reports Third Quarter 2025 Financial Results

Nov -13

Source: globenewswire.com

Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct -28

Source: businesswire.com

Applied Therapeutics Provides Update Following Meeting with FDA

Sep -29

Source: globenewswire.com

Applied Therapeutics Reports Second Quarter 2025 Financial Results

Aug -13

Source: globenewswire.com

Applied Therapeutics Announces Key Leadership Appointments

Jun -17

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.55%)

6. Segments

Biopharmaceutical

Expected Growth: 10.55%

Applied Therapeutics, Inc.'s biopharmaceutical segment growth of 10.55% is driven by increasing demand for novel therapeutics, strategic partnerships, and a strong pipeline of innovative products. Additionally, the company's focus on rare genetic disorders and unmet medical needs has led to increased investment in R&D, further fueling growth.

7. Detailed Products

ALD-102

ALD-102 is a novel, orally administered, small molecule being developed for the treatment of Galactosemia, a rare genetic disorder.

AT-007

AT-007 is a novel, orally administered, small molecule being developed for the treatment of Diabetic Nephropathy, a complication of diabetes.

AT-001

AT-001 is a novel, orally administered, small molecule being developed for the treatment of Citrin Deficiency, a rare genetic disorder.

8. Applied Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Applied Therapeutics, Inc. is medium due to the presence of alternative treatments and therapies available in the market.

Bargaining Power Of Customers

The bargaining power of customers for Applied Therapeutics, Inc. is low due to the specialized nature of their products and services.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Applied Therapeutics, Inc. is medium due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for Applied Therapeutics, Inc. is high due to the growing demand for gene therapies and the presence of new entrants in the market.

Intensity Of Rivalry

The intensity of rivalry for Applied Therapeutics, Inc. is high due to the presence of established competitors in the market and the high stakes involved in the gene therapy industry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	-7.44%
Debt Cost	3.95%
Equity Weight	107.44%
Equity Cost	13.51%
WACC	14.22%
Leverage	-6.93%

11. Quality Control: Applied Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Puma Biotechnology

A-Score: 5.6/10

Value: 7.4

Growth: 6.1

Quality: 8.7

Yield: 0.0

Momentum: 9.5

Volatility: 2.0

1-Year Total Return ->

Ligand Pharmaceuticals

A-Score: 4.8/10

Value: 4.4

Growth: 4.4

Quality: 3.9

Yield: 0.0

Momentum: 10.0

Volatility: 6.0

1-Year Total Return ->

iTeos Therapeutics

A-Score: 4.6/10

Value: 7.8

Growth: 3.6

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 4.3

1-Year Total Return ->

Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.2

Growth: 3.6

Quality: 7.2

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

Ardelyx

A-Score: 3.8/10

Value: 6.8

Growth: 6.2

Quality: 4.7

Yield: 0.0

Momentum: 3.0

Volatility: 2.0

1-Year Total Return ->

Applied Therapeutics

A-Score: 2.8/10

Value: 6.2

Growth: 6.9

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

17.14%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

14.22%

Applied Therapeutics, Inc. - US03828A1016

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on APLT

1.c. Company Highlights

Strong Momentum

Better Quality

Medium Volatility

Earnings Miss

More Volatile

Average Growth

Revenues Beats

Cheaper

Weak Momentum

Revenues Miss

Average Quality

Earnings Beats

Lower Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.55%)

6. Segments

Biopharmaceutical

Expected Growth: 10.55%

7. Detailed Products

ALD-102

AT-007

AT-001

8. Applied Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Applied Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.22$

Current Price

0.22$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA